



CORRECTION

## Correction to: Preparation and Preclinical Evaluation of Inhalable Particles Containing Rapamycin and Anti-Tuberculosis Agents for Induction of Autophagy

Anuradha Gupta<sup>1</sup> · Deepak Sharma<sup>1</sup> · Jairam Meena<sup>2</sup> · Sanketkumar Pandya<sup>1</sup> · Madhur Sachan<sup>1</sup> · Sadan Kuma<sup>1</sup> · Kavita Singh<sup>1</sup> · Kalyan Mitra<sup>1</sup> · Sharad Sharma<sup>1</sup> · Amulya K. Panda<sup>2</sup> · Pushpa Gupta<sup>3</sup> · Umesh Datta Gupta<sup>3</sup> · Amit Misra<sup>1</sup>

Published online: 19 April 2022

© Springer Science+Business Media, LLC, part of Springer Nature 2022

**Correction to:** Pharm Res (2016) 33:1899–1912  
<https://doi.org/10.1007/s11095-016-1926-0>

The correct version of Fig. 7 appears here. The image in Panel VI (earlier, “RAP-TRE”) has been replaced with the correct image. Sub-panels of have been re-labelled.

**Publisher's Note** Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

---

The original article can be found online at <https://doi.org/10.1007/s11095-016-1926-0>.


---

✉ Amit Misra  
amit\_misra@cdri.res.in

<sup>1</sup> Pharmaceutics Division, CSIR-Central Drug Research Institute, Sector 10A, Jankipuram Extension, Lucknow 226031, India

<sup>2</sup> National Institute of Immunology, Aruna Asaf Ali Marg, New Delhi 110067, India

<sup>3</sup> National JALMA Institute for Leprosy and Other Mycobacterial Diseases, ICMR, Tajganj, Agra 282001, India



**Fig. 7** Histopathology of lung in animals that were: (I) Infected, untreated (II) Infected + treated with Inhalation – Rap particles: daily dosing (I-RAP 10 D) for 10 days (III) Infected + Inhalation – Rap particles: alternate day dosing (I-RAP 10 ALT) (IV) Infected + Inhalation-Rap particles: weekly dosing (I-RAP 10 WKLY) (V) Infected + Inhalation – Rap trehalose particles particles: daily dosing (I-RAP 10 TRE-D) (VI) Infected + Oral Isoniazid-Rifabutin (125 µg) + Inhalation-Isoniazid Rifabutin particles: daily dosing (O-INH-RFB + I-INH-RFB-D) (VII) Infected + Oral Isoniazid-Rifabutin (125 µg) + Inhalation – Isoniazid Rifabutin particles: daily dosing (O-INH-RFB + I-RAP-D) (VIII) Infected + Inhalation—Isoniazid-Rifabutin-Rap particles: daily dosing (I-INH + RFB + RAP-D) (IX) Infected+Inhalation – Blank PLGA particles: daily dosing (I-BLK-D)